NCT07474727 2026-03-16
A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer
Multitude Therapeutics Inc.
Phase 2 Not yet recruiting
Clinical Trials
14 trialsNCT07391566 2026-02-06
LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation
Luye Pharma Group Ltd.
Phase 1/2 Not yet recruiting
NCT07381764 2026-02-02
ROMANCE - GOIM
Gruppo Oncologico Italia Meridionale
Phase 2 Not yet recruiting
NCT07363408 2026-01-23
Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer
City of Hope Medical Center
Phase 1 Not yet recruiting
NCT07094893 2026-01-14
ARIEL-ENGIC
Gruppo Oncologico del Nord-Ovest
Phase 4 Not yet recruiting
NCT07229846 2026-01-08
A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation
Harbin Medical University
Phase 2 Not yet recruiting
NCT07271355 2025-12-09
Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial
City of Hope Medical Center
Phase 3 Not yet recruiting
NCT07150403 2025-09-08
Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer
Federation Francophone de Cancerologie Digestive
Phase 2 Not yet recruiting
NCT07134205 2025-08-21
The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer
Shanghai JMT-Bio Inc.
Phase 3 Not yet recruiting
NCT07059338 2025-07-10
HERBIC
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07004413 2025-06-04
FIRE-11
Charite University, Berlin, Germany
Phase 3 Not yet recruiting
NCT06963502 2025-05-09
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT05427669 2022-10-07
AFFORD
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT04034173 2019-07-26
Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation
Ludwig-Maximilians - University of Munich
Phase 2 Not yet recruiting